Novelos Therapeutics has discontinued the development programme for its non-small cell lung cancer (NSCLC) candidate drug NOV-002 as the primary and secondary endpoints were not met in the Phase III trial.

Adding NOV-002 to paclitaxel and carboplatin chemotherapy did not vary in terms of efficacy-related endpoints or recovery from chemotherapy toxicity versus chemotherapy alone.

The randomised, controlled Phase III trial enrolled 903 patients with Stage IIIb / IV NSCLC, encompassing 100 clinical sites in 12 countries.

Novelos is continuing NOV-002 Phase II development to treat breast cancer and the trial results are expected in the third quarter of 2010.